French consensus regarding precautions during tracheostomy and post-tracheostomy care in the context of COVID-19 pandemic.


Journal

European annals of otorhinolaryngology, head and neck diseases
ISSN: 1879-730X
Titre abrégé: Eur Ann Otorhinolaryngol Head Neck Dis
Pays: France
ID NLM: 101531465

Informations de publication

Date de publication:
May 2020
Historique:
pubmed: 21 4 2020
medline: 23 5 2020
entrez: 21 4 2020
Statut: ppublish

Résumé

Tracheostomy post-tracheostomy care are regarded as at high risk for contamination of health care professionals with the new coronavirus (SARS-CoV-2). Considering the rapid spread of the infection, all patients in France must be considered as potentially infected by the virus. Nevertheless, patients without clinical or radiological (CT scan) markers of COVID-19, and with negative nasopharyngeal sample within 24h of surgery, are at low risk of being infected. Instructions for personal protection include specific wound dressings and decontamination of all material used. The operating room should be ventilated after each tracheostomy and the pressure of the room should be neutral or negative. Percutaneous tracheostomy is to be preferred over surgical cervicotomy in order to reduce aerosolization and to avoid moving patients from the intensive care unit to the operating room. Ventilation must be optimized during the procedure, to limit patient oxygen desaturation. Drug assisted neuromuscular blockage is advised to reduce coughing during tracheostomy tube insertion. An experienced team is mandatory to secure and accelerate the procedure as well as to reduce risk of contamination.

Identifiants

pubmed: 32307265
pii: S1879-7296(20)30096-X
doi: 10.1016/j.anorl.2020.04.006
pmc: PMC7144608
pii:
doi:

Types de publication

Practice Guideline Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

167-169

Informations de copyright

Copyright © 2020. Published by Elsevier Masson SAS.

Références

Laryngoscope. 2003 Oct;113(10):1777-9
pubmed: 14520105
Clin Chest Med. 2008 Jun;29(2):323-8, vii
pubmed: 18440440
Crit Care. 2018 Aug 17;22(1):195
pubmed: 30115127
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337

Auteurs

P Schultz (P)

Service d'ORL et de chirurgie cervico-faciale, hôpital de Hautepierre, avenue Molière, 67098 Strasbourg, France. Electronic address: philippe.schultz@chru-strasbourg.fr.

J-B Morvan (JB)

Service d'ORL et de chirurgie cervico-faciale, hôpital d'instruction des armées Saint-Anne, 2, boulevard Sainte-Anne, 83000 Toulon, France.

N Fakhry (N)

Service d'ORL et de chirurgie cervico-faciale, hôpital de la Conception, 147, boulevard Baille, 13005 Marseille, France.

S Morinière (S)

Service d'ORL et de chirurgie cervico-faciale, CHRU Bretonneau-Tours, 2, boulevard Tonnellé, 37044 Tours, France.

S Vergez (S)

Service d'ORL et de chirurgie cervico-faciale, CHU Rangueil-Larrey, 24, chemin de Pourvourville, 31400 Toulouse, France; Service de chirurgie, Institut universitaire du cancer de Toulouse, 1, avenue Irène Joliot-Curie, 31100 Toulouse, France.

C Lacroix (C)

Service d'ORL et de chirurgie cervico-faciale, hôpital européen Georges-Pompidou, Assistance publique-Hôpitaux de Paris, 20, rue Leblanc, 75015 Paris, France.

S Bartier (S)

Service d'ORL et de chirurgie cervico-faciale, centre hospitalier intercommunal de Créteil, 40, avenue de Verdun, 94010 Créteil, France.

B Barry (B)

Service d'ORL et de chirurgie cervico-faciale, hôpital Bichat-Claude-Bernard, 46, rue Henri-Huchard, 75018 Paris, France.

E Babin (E)

Service d'ORL et de chirurgie cervico-faciale, CHU Caen Normandie, avenue Côte de Nacre, 14000 Caen, France.

V Couloigner (V)

Service d'ORL et de chirurgie cervico-faciale pédiatriques, hôpital Necker-Enfants-Malades, Assistance publique-Hôpitaux de Paris, 149, rue de Sèvres, 75743 Paris, France.

I Atallah (I)

Service d'ORL et de chirurgie cervico-faciale, CHU Grenoble Alpes, boulevard de la Chantourne, 38700 La Tronche, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH